NAFLD and NASH Biomarkers in Detection, Diagnosis and Monitoring
This book provides a comprehensive overview of the diagnosis and management of Non-alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatis (NASH). Basic principles of disease progression, the genetic and nutritional basis of NAFLD and NASH a
- PDF / 4,821,775 Bytes
- 239 Pages / 439.43 x 683.15 pts Page_size
- 32 Downloads / 142 Views
123
NAFLD and NASH
Manuel Romero-Gomez Editor
NAFLD and NASH Biomarkers in Detection, Diagnosis and Monitoring
Editor Manuel Romero-Gomez UCM Digestive Diseases Virgen del Rocio University Hospital Sevilla Spain SeLiver Group Institute of Biomedicine of Seville Sevilla Spain University of Seville Sevilla Spain
ISBN 978-3-030-37172-2 ISBN 978-3-030-37173-9 (eBook) https://doi.org/10.1007/978-3-030-37173-9 © Springer Nature Switzerland AG 2020 This work is subject to copyright. All rights are reserved by the Publisher, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed. The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use. The publisher, the authors and the editors are safe to assume that the advice and information in this book are believed to be true and accurate at the date of publication. Neither the publisher nor the authors or the editors give a warranty, expressed or implied, with respect to the material contained herein or for any errors or omissions that may have been made. The publisher remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. This Springer imprint is published by the registered company Springer Nature Switzerland AG The registered company address is: Gewerbestrasse 11, 6330 Cham, Switzerland
Foreword
This book addresses current state of the art on the development of biomarkers in different scenarios of the disease: general population and primary care, in pediatric patients, and in patients with chronic liver diseases at risk of progression to cirrhosis, liver cancer and extrahepatic outcomes. Biochemical biomarkers including routine methods and omics from genetic to proteomic and metabolomic and imaging biomarkers from ultrasonography and transient elastography to magnetic resonance have been addressed focusing on clinical utility. Authors from all over the world (Spain, Israel, Australia, Italy, Switzerland, the United Kingdom, Greece, Brazil, and Chile) highly motivated and expert on NAFLD participated enthusiastically in this book. This work includes the thoughts and knowledge of the authors together with the current evidence available. In this evolving area, the performance of this work should be useful for the decision-making process in clinical practice of physicians working on all the levels of Health System. We hope you enjoy reading it. Thank you. Manuel Romero-Gomez UCM Digestive Diseases, Virgen del Rocio University Hospital Sevilla, Spain SeLiver Group, Institute of Bi
Data Loading...
